AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06782672 — intervention group
Intervention type: OTHER
Intervention: Experimental memory task
Description: First, a quiet period with the viewing of a documentary film (8min).~Then, participants will perform two 5-minute memory tasks of different difficulty levels (memorizing 3 letters corresponds to the easy level vs. 7 letters to the difficult level), separated by a 5-minute break. The order of difficulty will be counterbalanced.~At the end of each difficulty level, self-report measures assessed by the following questions will be collected:~* How much effort did you exert during the task?;~* How difficult did you find the task?~* How motivated were you to perform the task? Responses will be in Likert scale format, ranging from 1 (no effort at all, very easy, not at all motivated, respectively) to 7 (a lot of effort, very difficult, very motivated, respectively).
Study NCT06782672 — intervention group
Intervention type: OTHER
Intervention: Questionnaire and semi-structured psychological interview
Description: psychopathological measures collected using questionnaires:~* Beck Depression Inventory (BDI-II): mood~* State-Trait Anxiety Inventory (Form Y) (STAY-Y): anxiety~* Multidimensional Fatigue Inventory, 20-item version (MFI-20=): fatigue~* General Self-Efficacy Scale (GSES): defeatist beliefs~* Clinical Assessment Interview for Negative Symptoms (CAINS) : psychotic symptoms for the psychotic disorders group
Study NCT06783660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peptide-loaded collagen sponge and collagen gel complex
Description: A piece of peptide-loaded collagen sponge (Regenomer®) and collagen gel complex
Study NCT06783660 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen sponge
Description: Type 1 Collagen sponge (Regenomer)
Study NCT06783491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin (MM)
Description: Mitomycin 30mg/m2/4 litres of perfusion liquid (dextrose 1.5%). Single intraoperative dose.
Study NCT06783491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
Description: FOLFOX6 consists in oxaliplatin 85 mg/m2 iv. on day 1, 5FU 400 mg/m2 iv. in bolus followed by 2400 mg/m2 in a continuous infusion for 46 hours. Leucovorin: 400mg/m2 folinic acid (racemid dl) in a continuous infusion for 2 hours. Repeat every 2 weeks. Haematological recovery to ANC >1.5x109/L and platelets >75x109/L should be ensured prior to Day 1 of each 14-day cycle.
Study NCT06783491 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Cytoreductive surgery will be defined as complete tumour resection including oncologic colectomy and adjacent structures with suspicious of infiltration to achieve a R0, bilateral oophorectomy is recommended in post-menopausal women
Study NCT06783491 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cytoreductive surgery
Description: Cytoreductive surgery will be defined as complete tumour resection including oncologic colectomy and adjacent structures with suspicious of infiltration to achieve a R0, bilateral oophorectomy is recommended in post-menopausal women
Study NCT06787820 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: The musical intervention conducted at the senior home focused on the development of rhythmic and vocal skills, as well as the creation of educational experiences that promoted the acquisition of these competencies. To achieve this, both conventional percussion instruments, such as claves, tambourines, woodblocks, and triangles, and unconventional elements, such as buckets played with drumsticks, sheets of paper, spoons, ribbons, elastic bands, and a parachute, were used to mark the rhythm during the singing sessions. The selected songs were chosen based on the musical styles mentioned by the participants during the pre-intervention interview. Furthermore, participants were given the opportunity to showcase their progress at the end of the activity, with the aim of sharing these achievements with family and friends at the home.
Study NCT06785974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Daily 20mg atorvastatin.
Study NCT06785974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily Placebo in combination with ICI-therapy
Study NCT06783465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital therapeutics session
Description: During the digital therapeutics session, the patient performs tasks by handling objects according to instructions displayed by the device. A camera records the task performance, and the system analyzes the task performance.
Study NCT06787157 — intervention group
Intervention type: OTHER
Intervention: Prediction Model Construction
Study NCT06784596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsulting supported training
Description: Patients in this group will be provided with training the day before surgery, on the morning of surgery and on the day of discharge, and will receive teleconsulting services at the 1st, 2nd, 3rd, 4th, 5th, 6th, 8th, 10th and 12th weeks after discharge. will be given.
Study NCT06787118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD oil
Description: Patients will receive CBD-oral solution 2.5 mg/kg PO BID for a total of 12 weeks.
Study NCT06787118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will receive placebo for a total of 12 weeks.
Study NCT06787300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stories that Empowered Mother
Description: this intervention is made by resercher for this research.
Study NCT06787898 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group R: retrolaminar block performed group
Description: Patients were placed on their side and then T9, T10 vertebrae were marked. After the skin was cleaned and the area was covered with sterile drape. A linear ultrasound probe (6-13 Hz, Hitachi Europe Ltd, Tokyo, Japan) was placed in the middle of the vertebral bodies to image the T9, T10 vertebraes. An experienced anaesthesiologist in RLB performed the procedures with a USG-guided 1-15 Hz convex probe (8-4, Hitachi Europe Ltd, Tokyo, Japan) by in-plane approach. A puncture needle (21Gx100mm, USG-Type CCR, Vygon Co. Ltd. Ecouen, France) was inserted 1 cm from the probe at a 45-degree angle to the skin, targeting the lamina of the desired vertebra. The needle was gently withdrawn to ensure that no blood or cerebrospinal fluid was present. 10 mL of 0.25% bupivacaine (Bupivon®) was injected posterior to each lamina (T9, T10), totalling 20 mL
Study NCT06787898 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Group C - Placebo
Description: Patients were placed on their side and then T9, T10 vertebrae were marked. After the skin was cleaned and the area was covered with sterile drape. A linear ultrasound probe (6-13 Hz, Hitachi Europe Ltd, Tokyo, Japan) was placed in the middle of the vertebral bodies to image the T9, T10 vertebraes. An experienced anaesthesiologist in RLB performed the procedures with a USG-guided 1-15 Hz convex probe (8-4, Hitachi Europe Ltd, Tokyo, Japan) by in-plane approach. A puncture needle (21Gx100mm, USG-Type CCR, Vygon Co. Ltd. Ecouen, France) was inserted 1 cm from the probe at a 45-degree angle to the skin, targeting the lamina of the desired vertebra. The needle was gently withdrawn to ensure that no blood or cerebrospinal fluid was present. 10 mL of 0.25% bupivacaine (Bupivon®)was injected posterior to each lamina (T9, T10), totalling 20 mL.
Study NCT06784154 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: Non-interventional
Study NCT06785987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous Lidocaine Infusion
Description: Maintained with sevoflurane and continuous lidocaine infusion under dosage: 1.5 mg/kg/hr
Study NCT06785987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intermittent fentanyl infusion
Description: Maintained with volatile anesthetic gas (sevoflurane) and intermittent fentanyl infusion.
Study NCT06785987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous remifentanil Infusion
Description: Maintained with sevoflurane and continuous remifentanil infusion under dosage: 3-5μg /kg/hr
Study NCT06785233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Adjustable Intragastric Balloon
Description: Weight Loss with a 12-Month Non-Adjustable Intragastric Balloon is More Effective Compared to a 6-Month Balloon.
Study NCT06785233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORBERA365
Description: endoscopic treatment of overweight and mild obesity using a 12-month non-adjustable intragastric balloon
Study NCT06788054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intradialysis exercise
Description: moderate intensity aerobic and muscular resistance exercise protocol lasting 12 weeks
Study NCT01089452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril
Description: Perindopril 5mg for 4 weeks, forced titration to 10mg for 8 weeks
Study NCT01089452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril/amlodipine
Description: Perindopril/amlodipine 5/5mg, 10/5mg, 10/10mg: 4 weeks duration at each dose; forced titration.
Study NCT01089452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olmesartan/amlodipine
Description: Olmesartan/amlodipine 20/5mg, 40/5mg, 40/10mg: 4 weeks at each dose; forced titration.
Study NCT05013502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: empagliflozin 10mg PO once daily
Study NCT06785246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Grasshopper dashboard
Description: Computer dashboard application for radiologists that displays relevant clinical information directly from the medical record
Study NCT06785610 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsulase®
Description: Capsulase® supplement daily administration after surgery
Study NCT06224218 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Port Robotic Surgery
Description: Single port Robotic surgery will remove the whole prostate
Study NCT06224218 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Surgery
Description: Laser enucleation will remove chips of the prostate but keeping intact the prostate capsule.
Study NCT06783114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Botulinum Toxin Type A for injection (YY001)
Description: Single treatment, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), intramuscular injection, the total injection dose is 200 U (low dose cohort)/ 300 U (medium dose cohort)/ 400 U (high dose cohort).
Study NCT06783114 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX®
Description: Single treatment, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), intramuscular injection, the total injection dose is 200 U (low dose cohort).
Study NCT06783114 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single treatment, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), intramuscular injection.
Study NCT06782568 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound Scan
Description: Participants will undergo an ultrasound scan of insulin injection sites at baseline and after 6 months.
Study NCT06783868 — intervention group
Intervention type: DEVICE
Intervention: Catheter Ablation
Description: Catheter Ablation is commonly performed with radiofrequency or cryotherapy to maintain a rhythm control strategy if patients can no longer tolerate their symptoms or are no longer controlled on AVNB or AAD. The procedure leads to significant symptom improvement even though there may be insignificant AF recurrence at one year. At Kansas City Heart Rhythm Institute, CA may be performed with radiofrequency ablation (Tactiflex Ablation Catheter, Abbott Cardiovascular, Minneapolis, MN) or pulsed field ablation (PulseSelectTM, Abbott Cardiovascular or FaraWaveTM, Boston Scientific, Marlborough, MA), performed with EnsiteX (Abbott Cardiovascular) or Carto3 (Biosense Webster, Irvine, CA) mapping software.
Study NCT06783868 — intervention group
Intervention type: DRUG
Intervention: Market-approved AVNB, OAC and AAD
Description: Used per protocol for the duration of the trial.
Study NCT06786468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early palliative care integration
Description: The patients will attend palliative care clinic once a month during the first three months together with routine oncology clinic visits
Study NCT06786468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard systemic treatment for advanced lung cancer
Description: Standard systemic treatment for advanced lung cancer
Study NCT06786468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard systemic treatment for advanced lung cancer
Description: Standard systemic treatment for advanced lung cancer
Study NCT06787768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology Enriched Rehabilitation Gym
Description: The intervention is an 8-week long rehabilitation programme delivered entirely through technology, including virtual reality (immersed and non-immersed), treadmills, weight suspension and movement resistance, and power assistance equipment located in a gym-like space on a university campus. Individual programs are designed, supervised, and reviewed by a physiotherapist using principles of intensity, feedback, cognitive engagement, and aerobic activity to address the goals identified by the participant and scores from outcome measures at baseline. Participants attend a minimum of two times per week and can attend daily for the two hour group based circuit class.
Study NCT06787092 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bladder cycling
Description: started by the instillation of the sterile water in the bladder in amount equal to the estimated bladder capacity. Then the amount will be gradually increased till the patient can withstand filling the bladder with 250 cc of sterile saline for 2 hours.
Study NCT06787391 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurotization of Spinal Accessory Nerve To Supra-Scapular in children with OBPP with deficiency of Shoulder External Rotation
Description: Neurotization of Spinal Accessory Nerve To Supra-Scapular Nerve in children with OBPP presented with deficiency of Shoulder External Rotation.
Study NCT06787391 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurotization of Spinal Accessory Nerve To Supra-Scapular Nerve
Description: Just to assess clinical outcomes after Neurotization of spinal accessory nerve to Supra-Scapular Nerve in patients with deficiency of Shoulder External Rotation
Study NCT06787560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7 CAR-T cells injection
Description: Each subject receive CD7 CAR T-cells by intravenous infusion
Study NCT06787560 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allo-HSCT
Description: allogeneic hematopoietic stem cell transplantation
Study NCT06786962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality Hypnosis
Description: The experimental group of 22 participants consists of a hypnosis intervention using a virtual reality device (HypnoVR®).~Participants are seated in a quiet area of the unit:~They choose a visual scenario from among 3 proposals, guaranteeing the conditions of a restorative environment. During each session, the same script (support mode) is spoken and the same music (serenity program with soothing tones) is associated with the script. Each participant is fitted with a virtual reality mask and a headset with active noise reduction.
Study NCT06786962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control arm (SEQ):
Description: Restoration time~Participants are seated in a quiet area of the unit. The control group of 21 participants consists of a break with the following instructions and suggestions:~Take advantage of this break, this time just for you, to recharge your batteries. Sit in this armchair and I suggest you think of something pleasant and comfortable.
Study NCT06095258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine treatment
Description: About four to six Chinese medicine practitioners with five to twenty years of clinical work experience will be responsible for patient diagnosis and prescription treatment, and use a uniformly designed data collection form to record the patient's medical history, clinical symptoms and signs, tongue and pulse conditions, and other information. Patients in the treatment group will receive individualized Chinese medicine treatment prescriptions. Patients in the control group received conventional Western medicine treatment, and about 3 to four Western medicine practitioners with five to twenty years of work experience will be responsible for the conventional medicine prescription. The treatment of the two groups will last for four weeks, and the patients will be followed up for four weeks after the treatment. A patient diary will be provided to all participants for recording the drug compliance and any adverse event during the treatment period.
Study NCT06095258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Western medicine treatment
Description: Western medicine doctors will mainly use symptomatic drugs to treat long COVID. For example, cough medicine (such as codeine), bronchodilators (such as ventolin), expectorants (such as fluimucil) and so on are used to treat cough, shortness of breath, or other respiratory symptoms. Non-steroidal anti-inflammatory painkillers (such as panadol) are often used for treating headaches, and sedative-hypnotic drugs (such as stilnox) are often used to treat insomnia.
Study NCT05569148 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Faricimab PFS Configuration
Description: Participants will receive a single intravitreal (IVT) injection of the 6-milligram (mg) faricimab dose formulation delivered via prefilled syringe (PFS) with a co-packaged injection filter needle.
Study NCT06328283 — intervention group
Intervention type: OTHER
Intervention: measure of Glutamine synthetase and BCLFAF1
Description: compare Glutamine synthetase and BCLFAF1 in cases and controls
Study NCT06288282 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No intervention will be used.
Study NCT05861895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF158K1 /Arm 2 mg/m²
Description: Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
Study NCT05861895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF158K1 /Arm 6 mg/m²
Description: Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
Study NCT05861895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF158K1 /Arm 15 mg/m²
Description: Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
Study NCT05861895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF158K1 /Arm 30 mg/m²
Description: Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
Study NCT05861895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF158K1 /Arm 45 mg/m²
Description: Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
Study NCT05861895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HF158K1 /Arm 60 mg/m²
Description: Duration of infusion: HF158K1 is diluted using 5% (50 mg/ml) glucose injection or 0.9% sodium chloride injection (saline) to a total volume of 250 ml and is administered through intravenous infusion for 90 ± 10 min.
Study NCT06148155 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-RG2 PET Imaging
Description: Intravenous injection of 1.8 MBq \[0.05MCi\]/kg of \[68Ga\]Ga-NOTA-RG2 in a single dose.
Study NCT06785662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The budesonide nasal irrigation
Description: The participant in this group used a solution containing 1 milligram of budesonide mixed with 240 milliliters of normal saline in a squeeze bottle (Cleanoze®) for nasal irrigation. The procedure will be performed once daily while leaning slightly forward over a sink.
Study NCT06785662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The budesonide nasal spray
Description: The participants in this group used a nasal spray containing 64 micrograms of budesonide per spray, with two sprays per nostril administered twice daily (morning and evening).
Study NCT06786026 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: bevacizumab
Description: bevacizumab
Study NCT06786026 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: QL1706
Description: Bispecific antibody (bsAB) targeting PD-1 and CLTA-4
Study NCT06786026 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nab paclitaxel
Description: albumin-bound paclitaxel
Study NCT06783257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonorasan fumarate injection1
Description: 40 mg (20 mg bid, 6 hours apart, Day1) + 20 mg (Day2\&3, q24h), ivd, 30 min, administered for 3 days
Study NCT06783257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonorasan fumarate injection2
Description: 40mg（Day1）+20mg（Day 2\&3），ivd，30min，q24h，administered for 3 days